Clinical Trials · NCT07160257
A Study to Evaluate the Effect of Maridebart Cafraglutide on Insulin Sensitivity and β-cell Function in Participants With Type 2 Diabetes Mellitus
- Phase
- Phase 1
- Recruitment status
- Active Not Recruiting
- Sponsor
- Amgen
- Enrollment
- 56
- Start date
- Aug 2025
- Locations
- 1 site, United States
- Primary endpoint
- Change from Baseline in M-value from Hyperinsulinemic-euglycemic Clamp at Week 25